SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor Technologies is trending strongly following reports that a former US President is instructing representatives to buy $200 billion in mortgage bonds, a move expected to significantly lower mortgage rates and enhance housing affordability. The community is highly optimistic, anticipating a substantial surge in the housing market and a potential short squeeze, with many celebrating this development as a major catalyst for the company's prospects.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending as the market anticipates its pivotal role in next-generation AI infrastructure, driven by Marvell's strategic acquisitions in optical interconnects and NVIDIA's recent emphasis on photonics for AI platforms at CES. The community is actively debating POET's disruptive Optical Interposer technology, which uses light-based communication to address critical speed and power bottlenecks in AI data centers, and its potential for substantial revenue growth through key industry partnerships. Many investors view the current lack of immediate announcements as a sign of large-scale deals under non-disclosure agreements, positioning the company for a significant market re-rating in the burgeoning photonics sector.

Rocket Cos., Inc. engages in the provision of a suite of services related to homeownership and other personal financial transactions. It operates through the following segments: Direct to Consumer and Partner Network. The Direct to Consumer segment consists of performance marketing and direct engagement through the Rocket Mortgage App. The Partner Network Segment focuses on partnerships with premier consumer-focused organizations, brokers and mortgage professionals who leverage the platform and scale to provide mortgage solutions to clients. The company was founded by Daniel Gilbert in 1985 and is headquartered in Detroit, MI.

Rocket Companies Inc - Ordinary Shares Class A

Rocket Companies (RKT) is trending following news of former President Trump's plans to stimulate the housing market, including instructing representatives to buy $200 billion in mortgage bonds and potentially banning institutional home purchases. This has ignited community discussion around an impending refinance boom and increased housing affordability, positioning RKT's integrated mortgage and real estate platform for a significant re-rating and potential new highs. Investors are actively debating the magnitude of this positive catalyst on RKT's business model.

Federal National Mortgage Association is a government-sponsored company, which engages in the provision of liquidity for purchases of homes and financing of multifamily rental housing and refinancing existing mortgages. It operates through the Single-Family and Multifamily segments. The Single-Family segment offers liquidity to the mortgage market and increases the availability and affordability of housing for single families. The Multifamily segment includes guaranty fees on mortgages and on multifamily mortgage loans. The company was founded in 1938 and is headquartered in Washington, DC.

Federal National Mortgage Association

Federal National Mortgage Association (FNMA) is trending amidst heightened speculation about its future, fueled by recent commentary from prominent figures regarding potential government-directed mortgage bond purchases and its substantial cash reserves. The community is actively discussing these developments as signals for the long-anticipated privatization, including a potential uplisting or IPO, which could significantly impact the housing market and mortgage rates. Noted investors are also expressing bullish sentiment, further intensifying the conversation around the mortgage giant's path out of conservatorship.

Aclarion, Inc. is a healthcare technology company, which engages in the provision of Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. It utilizes Artificial Intelligence to assist in quality control processes that flag spectroscopy data indicative of a poor MRS study. It offers NOCISCAN Suite, a revolutionary software suite that works with existing high field Magnetic Resonance systems and Magnetic Resonance Spectroscopy pulse sequence packages using an optimized protocol to conduct MRS exams of lumbar discs. The company was founded by James C. Peacock, David S. Bradford, and Jeffrey Lotz in 2008 and is headquartered in Broomfield, CO.

Aclarion Inc

Aclarion Inc. is attracting significant attention following its update on triple-digit growth for its AI back pain platform, robust cash position, and no debt. The community is buzzing about the extremely low float and potential for a massive short squeeze, drawing comparisons to $SMX. However, some traders voice concerns over perceived market manipulation attempting to suppress the price, despite the strong underlying fundamentals.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

ARDX is trending as investors digest the potential impact of Fosun Pharma's Wan Ti Le being included on China's National Reimbursement Drug List and analysts anticipate target price raises due to strong IBSRELA sales. The community is weighing potential revenue from China and speculating on milestone payments, while also discussing concerns about patent infringement and generic competition. Some investors express frustration with the stock's price movement despite positive developments, awaiting a CMS resolution.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending following positive FDA feedback, confirming its existing data is sufficient for a Biologic License Application for its lead drug in hidradenitis suppurativa, de-risking its approval pathway. The community is buzzing with renewed buyout speculation, particularly regarding a potential acquisition by a major pharmaceutical firm, with many anticipating a significant re-rating of the stock.

flyExclusive, Inc. engages in owning and operating jet aircraft for private jet passengers. It manages all aspects of the customer experience, in-house maintenance, repair, and overhaul services, including paint, interiors, and avionics capabilities. The company was founded by Thomas James Segrave, Jr. in 2015 and is headquartered in Kinston, NC.

flyExclusive Inc. - Ordinary Shares - Class A

flyExclusive is experiencing a surge in attention following its announcement as an authorized Starlink Aviation dealer, which allows the company to install high-speed internet on its private jet fleet and for third-party clients. This development is fueling widespread discussion and speculative trading activity, with the community weighing its potential for new revenue streams against market concerns regarding recent stock offerings.

Kratos Defense & Security Solutions, Inc. engages in the provision of mission critical products, services and solutions for United States national security priorities. It operates through the Kratos Government Solutions (KGS) and Unmanned Systems (US) segments. The KGS segment consists of an aggregation of KGS operating segments, including microwave electronic products, space, satellite and cyber, training solutions. The US segment refers to the unmanned aerial, unmanned ground, unmanned seaborne and related command, control and communications system businesses. The company was founded on December 19, 1994, and is headquartered in Round Rock, TX.

Kratos Defense & Security Solutions Inc

Kratos Defense is currently trending as the broader defense sector surges, fueled by proposals for a significant increase in military spending and the U.S. Army's intent to acquire a million drones. Community discussion centers on KTOS's disruptive autonomous systems, large contract backlog, and expanding production, while some debate its high valuation amidst recent insider selling. This positions Kratos as a key player in the evolving landscape of affordable, mass-produced defense technologies.

Oscar Health, Inc. is a health insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

Oscar Health is attracting significant attention as the market keenly awaits congressional decisions on extending Affordable Care Act (ACA) subsidies, following a House-passed bill and ongoing bipartisan Senate negotiations for a potential extension. Community discussion is polarized, with many anticipating a substantial rally and potential short squeeze given the high short interest if an extension is secured, while skeptics foresee further downside if an agreement falters. Adding to the volatility, recent analyst upgrades suggest confidence in the company's long-term profitability and market positioning, independent of the immediate subsidy outcome.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Fortress Biotech (NASDAQ:FBIO) Stock Price Passes Above Two Hundred Day Moving Average - What's Next?

Fortress Biotech (NASDAQ:FBIO) Stock Price Passes Above 200 Day Moving Average - Should You Sell...

Fortress Biotech (NASDAQ:FBIO) Stock Price Passes Above 200-Day Moving Average - Here's What Happened

Fortress Biotech (NASDAQ:FBIO) Stock Price Crosses Above 200 Day Moving Average - Here's Why...

Envestnet Asset Management Inc. Sells 98,195 Shares of Fortress Biotech, Inc. $FBIO

Envestnet Asset Management Inc. lessened its holdings in Fortress Biotech, Inc. (NASDAQ:FBIO - Free Report) by 36.7% during the second quarter, according to its most recent 13F filing with the...

Fortress Biotech (NASDAQ:FBIO) Upgraded at Wall Street Zen

Wall Street Zen upgraded Fortress Biotech from a "hold" rating to a "buy" rating in a report on Sunday...

Fortress Biotech (NASDAQ:FBIO) Issues Earnings Results

Fortress Biotech (NASDAQ:FBIO - Get Free Report) announced its quarterly earnings results on Friday. The biopharmaceutical company reported $0.11 earnings per share (EPS) for the quarter, beating the...

Fortress Biotech (NASDAQ:FBIO) Rating Lowered to Hold at Wall Street Zen

Wall Street Zen downgraded Fortress Biotech from a "buy" rating to a "hold" rating in a report on Saturday...

Fortress Biotech (NASDAQ:FBIO) Stock Crosses Above Two Hundred Day Moving Average - Here's What Happened

Fortress Biotech (NASDAQ:FBIO) Shares Cross Above 200-Day Moving Average - Should You Sell...

Fortress Biotech (FBIO) Surpasses Q3 Earnings Estimates

Fortress Biotech (FBIO) delivered earnings and revenue surprises of +125.58% and -25.55%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Armata Pharmaceuticals, Inc. (ARMP) Reports Q3 Loss, Misses Revenue Estimates

Armata Pharmaceuticals (ARMP) delivered earnings and revenue surprises of 0.00% and -16.01%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Kamada (KMDA) Misses Q3 Earnings Estimates

Kamada (KMDA) delivered earnings and revenue surprises of -10.00% and +1.64%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. It operates through the Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development segments. Its products include Ximino, Targadox, Exelderm, Ceracade, and Luxamend. The company was founded in 2006 and is headquartered in Bay Harbor Islands, FL.

Fortress Biotech Inc

Yes — Rates Move Meaningfully Lower

Short-Term Dip, No Lasting Impact

No — Mostly Political Noise

Other – Comment Below

President Trump says he’s directing $200 billion into mortgage bond purchases to bring down rates and improve housing affordability. With questions around execution, authority, and real market impact, do you think this move will actually lower mortgage rates in 2026?

Will Trump’s Mortgage Bond Plan Actually Lower Rates in 2026?

FBIO
Fortress Biotech Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest FBIO News

FBIOFortress Biotech Inc